Keytruda Qlex

Keytruda Qlex is a combination of pembrolizumab, a programmed death receptor-1 (PD-1)-blocking antibody, and berahyaluronidase alfa, an endoglycosidase. This therapeutic drug is used for the treatment of:
Melanoma

• Non-Small Cell Lung Cancer (NSCLC)
• Malignant Pleural Mesothelioma (MPM)
• Head and Neck Squamous Cell Cancer (HNSCC)
• Urothelial Cancer
• Microsatellite Instability-High or Mismatch Repair Deficient Cancer
• Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC)
• Gastric Cancer
• Esophageal Cancer
• Cervical Cancer
• Hepatocellular Carcinoma (HCC)
• Biliary Tract Cancer (BTC)
• Merkel Cell Carcinoma (MCC)
• Renal Cell Carcinoma (RCC)
• Endometrial Carcinoma
• Tumor Mutational Burden-High (TMB-H) Cancer
• Cutaneous Squamous Cell Carcinoma (cSCC)
• Triple-Negative Breast Cancer (TNBC)

Recommended Dosage:
The recommended dosage of Keytruda Qlex is administered by subcutaneous injection into the thigh or abdomen by a healthcare provider. This innovative formulation offers a faster and more convenient way to receive treatment compared to the traditional intravenous (IV) infusion. While IV Keytruda requires approximately 30 minutes, Keytruda Qlex can be administered in just 1–2 minutes, reducing clinic time and improving patient comfort. Designed to deliver the same therapeutic benefit, this subcutaneous option enhances convenience for patients undergoing immunotherapy for various cancers while maintaining efficacy, safety, and treatment consistency under medical supervision.

• Treatment with Keytruda Qlex may be responsible for causing serious or fatal immune-mediated reactions involving important organs such as lungs, liver, colon, endocrine glands, or kidneys. Early identification and corticosteroid treatment are important. Discontinue treatment for life-threatening reactions and monitor patients closely during and after the completion of treatment.
• Serious hypersensitivity or infusion reactions, including anaphylaxis, can occur during or after the use of Keytruda Qlex injection. Symptoms include rash, fever, chills, hypotension, or dyspnea. Interrupt infusion quickly in case serious reactions occur. Permanently stop treatment for any grade 3–4 hypersensitivity and start appropriate medical management promptly.
• Patients receiving allogeneic HSCT before or after this treatment may experience serious or fatal complications such as hepatic veno-occlusive disease, graft-versus-host disease, or transplant rejection. Monitor closely for post-transplant immune-related complications and provide prompt, intensive supportive and immunosuppressive therapy.
• Keytruda Qlex treatment can harm a developing fetus because of its immune-modulating action on PD-1/PD-L1 pathways. Women of reproductive age should use effective contraception during treatment and for several months after the last dose. Administer only if the potential maternal benefit justifies the possible fetal risk.
• It is not known whether pembrolizumab passes into human milk; however, the risk for serious side effects in nursing infants exists. Women should avoid breastfeeding during treatment and for at least 4 months after the final dose to minimize risk to the infant.

What documents are required to import KEYTRUDA QLEX to India?

KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection can be imported by patients or government hospitals in the name of the patients only.
The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
• Patients diagnostic reports
• Patient ID proof (issued by the government of India)

How does the order get confirmed?

The order will be confirmed only after the receipt of:

• A valid prescription from the Doctor
• Import permit if applicable

Is KEYTRUDA QLEX available in India?

KEYTRUDA QLEX (bembrolizumab and Berahyaluronidase alfa-pmph injections) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator, providing input

• On the availability of Keytruda Qlex in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune, etc.)
• On availability in Gulf countries (Bahrain, Oman, Qatar, Kuwait, Iraq, Saudi Arabia, and the UAE).
• Medicine Price.
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
• Ensuring 100% transparency.

KEYTRUDA QLEX can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune, and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit.

IPN (Indian Pharma Network) can facilitate the supply of KEYTRUDA QLEX (prescription medicines) to all locations in the world and India after fulfilling the legal requirements (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Keytruda Qlex injection price in India.

We guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network can source KEYTRUDA QLEX (Cancer Treatment Medicines) from across the globe and can supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) can dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Keytruda Qlex®?

Pembrolizumab and Berahyaluronidase alfa-pmph is the Generic Name for the trade name drug Keytruda Qlex®.

What is the Manufacturer’s Name of Keytruda Qlex®?

Keytruda Qlex® is manufactured by Merck.

Is Keytruda Qlex approved by the FDA?

Yes. Keytruda Qlex is approved by the FDA. date of first approval: September 19, 2025.

What is the dosage and form of Keytruda Qlex® supplied?

Keytruda Qlex is supplied as an injection 395 mg pembrolizumab and 4,800 units berahyaluronidase alfa per 2.4 mL (165 mg/2,000 units per mL) in a single-dose vial. Also, it is supplied as 790 mg pembrolizumab and 9,600 units berahyaluronidase alfa per 4.8 mL (165 mg/2,000 units per mL) in a single-dose vial for subcutaneous use.

What are the most common side effects of Keytruda Qlex® injection?

The most commonly reported side effects of Keytruda Qlex® in combination with chemotherapy are nausea, fatigue, and musculoskeletal pain.

How much does Keytruda Qlex® injection cost in India?

Keytruda Qlex® is not yet approved in India. However, patients in India can legally access it through the provision called the Named Patient Program (NPP). Keytruda Qlex prices may fluctuate over time because of market dynamics and regulatory changes. For the most transparent and latest Keytruda Qlex cost in India, please call/WhatsApp +91-9310090915 or send an email to info@indianpharmanetwork.in.

Can Keytruda Qlex® injections be available in SAARC countries?

Apart from Gulf countries, Keytruda Qlex® can be accessed through import provisions like the Named Patient Program (NPP) in SAARC countries (India, Afghanistan, Maldives, Nepal, Bangladesh, Bhutan, Pakistan, and Sri Lanka). Indian Pharma Network (IPN) can help facilitate the legal supply of Keytruda Qlex® injection in these countries. We help provide legal access to this therapeutic drug through our reliable channels.

Is it safe to buy Keytruda Qlex® injection online in India?

Yes, one can buy Keytruda Qlex online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not yet registered or available in their country. We can help facilitate the legal supply of Keytruda Qlex® injection through legal channels.

What are the storage conditions of Keytruda Qlex® injections?

Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. It is not advisable to freeze or shake it.